Towards a Better Understanding of Diabetes Distress, Depression and Poor Glycaemic Control (DIA-LINK Study)
DIA-LINK
1 other identifier
observational
208
1 country
2
Brief Summary
The DIA-LINK Study is a prospective observational study analysing longitudinal associations and mediating links between diabetes distress (DD), depressive symptoms (DS) and glycaemic outcomes in people with type 1 diabetes (T1DM). A total of 200 people with T1DM with different levels of DD and DS are to be enrolled. At baseline, all participants are assessed for DD and DS, psychological and stress-related variables, self-reported self-management, HbA1c and inflammatory markers. This is followed by a 4-week ambulatory assessment period including continuous glucose monitoring (CGM), continuous activity tracking and daily event sampling regarding sleep, stress levels, mood and diabetes-related issues; additionally, cortisol levels are assessed on four days within this period. Three months after baseline, a follow-up assessment covers DD and DS levels, stress-related variables, self-reported self-management, HbA1c and final CGM assessment. The analyses aim to establish risk factors/protective factors regarding DD and DS, their relative impact on glycaemic outcomes and potential mediation of the associations by behavioural (e.g. self-management, physical activity), physical (e.g. heart rate variability, inflammatory activity) and mental variables (subjective stress level) in T1DM.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2018
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2018
CompletedFirst Submitted
Initial submission to the registry
January 4, 2019
CompletedFirst Posted
Study publicly available on registry
January 22, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2020
CompletedSeptember 27, 2024
September 1, 2024
2 years
January 4, 2019
September 25, 2024
Conditions
Outcome Measures
Primary Outcomes (3)
Depressive symptoms
Depressive symptoms are assessed using the 20-item Center for Epidemiologic Studies Depression Scale (CES-D), covering 20 symptoms of depression. Frequencies of the symptoms during the past week are scored on a 4-point Likert scale (from 0 - "rarely or non of the time" to 3 - "most or all of the time"). Item scores are summed to a total score ranging from 0 to 60, whereby higher values reflect higher depressive symptoms. A cut-off point at ≥ 22 points (found to have the best likelihood ratio for detecting depression within the German population) is used to establish elevated depressive symptoms in this study.
3-month follow-up
Diabetes Distress
Diabetes Distress is assessed as using the 20-item Problem Areas In Diabetes Scale (PAID). 20 potential problems related to living with diabetes are rated on a 5-point Likert scale (from 0 - "not a problem" to 4 - "serious problem"). Item scores are summed/transformed to a total score ranging from 0 to 100, whereby higher values reflect higher diabetes distress. A cut-off point at ≥ 40 points is commonly used to establish high diabetes distress, so too in this study.
3-month follow-up
HbA1c
HbA1c (estimated in %-points; mmol/mol values are calculated thereof) is used as a measure of glycaemic levels during past 3 months. It is estimated from a venous blood sample using high performance liquid chromatography (Tosho G11 analyser; meeting International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) standard) in this study. Higher values indicate less optimal glycaemic control, and values above 7.5% (58 mmol/mol) are considered to indicate glycaemic levels in need of improvement.
3-month follow-up
Secondary Outcomes (17)
"Time in range" of glucose levels
Continuous assessment over 4 weeks from baseline
Variability of glucose levels
Continuous assessment over 4 weeks from baseline
"Time in hypoglycaemia" of glucose levels
Continuous assessment over 4 weeks from baseline
"Time in hyperglycaemia" of glucose levels
Continuous assessment over 4 weeks from baseline
Activity time
Continuous assessment over 4 weeks from baseline
- +12 more secondary outcomes
Other Outcomes (8)
Coping with stress
Baseline
Resilience
Baseline
Life events
Baseline
- +5 more other outcomes
Study Arms (4)
No DD or DS
No diabetes distress or depressive symptoms reported (CES-D \< 22, PAID \< 40)
DD without DS
Diabetes distress but no depressive symptoms reported (CES-D \< 22, PAID ≥ 40)
DS without DD
Depressive symptoms but no diabetes distress reported (CES-D ≥ 22, PAID \< 40)
DD and DS
Both diabetes distress and depressive symptoms reported (CES-D ≥ 22, PAID ≥ 40)
Interventions
There is no intervention or group-specific procedure per observation groups. Each of the 4 groups is monitored using ecological momentary assessment (EMA) for diabetes-specific problems, mood, stress, diabete distress via a smartphone app over 26 days. Study is observational/non-interventional; specific groups are enrolled to enable specific comparisons between people with/without depressive symptoms and/or diabetes distress; no specific interventions are offered to neither group.
Eligibility Criteria
People with T1DM with different levels of diabetes distress (DD) and/or depressive symptoms (DS): Four groups of n = 50 persons each reporting 1. "no DD/no DS" vs. 2. "DD/no DS" vs. 3. "DS/no DD" vs. "DD and DS".
You may qualify if:
- Type 1 Diabetes
- Diabetes duration at least 1 year
- Age between 18 and 70 years
- Sufficient German language skills
- Informed consent
- Smartphone available
You may not qualify if:
- Capacity for consent lacking
- Illness with significant impairment of cognitive functioning (e.g. dementia)
- Severe somatic illness or mental disorder which interferes with study participation or might confound the results (dialysis-dependent renal failure; heart failure, i.e. New York Heart Association (NYHA) class III or IV; cancer requiring treatment; schizophrenia/psychotic disorder; bipolar disorder; severe eating disorder F50.0/F50.2; personality disorder)
- Terminal illness
- Being bedridden
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Norbert Hermannslead
- German Center for Diabetes Researchcollaborator
- University of Giessencollaborator
- Helmholtz Zentrum Münchencollaborator
Study Sites (2)
Diabetes Center Mergentheim
Bad Mergentheim, Baden-Wurttemberg, 97980, Germany
Research Institute of the Diabetes Academy Mergentheim, Diabetes Center Mergentheim
Bad Mergentheim, Baden-Wurttemberg, 97980, Germany
Related Publications (2)
Ehrmann D, Schmitt A, Priesterroth L, Kulzer B, Haak T, Hermanns N. Time With Diabetes Distress and Glycemia-Specific Distress: New Patient-Reported Outcome Measures for the Psychosocial Burden of Diabetes Using Ecological Momentary Assessment in an Observational Study. Diabetes Care. 2022 Jul 7;45(7):1522-1531. doi: 10.2337/dc21-2339.
PMID: 35613338BACKGROUNDSchmitt A, Ehrmann D, Kuniss N, Muller N, Kulzer B, Hermanns N. Assessing fear of complications in people with type 1 and type 2 diabetes with the Fear of Diabetes Complications Questionnaire. Health Psychol. 2023 Sep;42(9):674-685. doi: 10.1037/hea0001304. Epub 2023 Jul 27.
PMID: 37498716DERIVED
Biospecimen
HbA1c; Cortisol; Markers of inflammation (hsCRP, IL-6, IL-1Ra, IL-18)
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bernhard Kulzer, PhD
Research Institute of the Diabetes Acadmey Mergentheim
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof. Dr. phil.
Study Record Dates
First Submitted
January 4, 2019
First Posted
January 22, 2019
Study Start
July 1, 2018
Primary Completion
June 30, 2020
Study Completion
June 30, 2020
Last Updated
September 27, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share